LT, You are correct that most investors who have read the release weren't overly impressed. A half million shares traded on a gain of 3 cents. We still have a lot of shares for sale out there by someone or it could be that most realize that a press release like this one just trades right back down.
IMO, the company is just basically in a holding pattern waiting for something to happen with Abbott/GE and they have been for quite some time. This sale by Abbott had to be initiated at least 6 - 12 months ago. Once they got down to talking price, I doubt if Abbott would want to cough up a milestone and get nothing in return. GE cannot press on because they don't own it yet. When the sale of this division is completed as expected in the second half of the year, GE would then be able to put whatever money is necessary to press on.
Until then, BioCurex is just going to continue to try to keep the stock price up, find new licensing partners and work on the test themselves. I think the sale has just complicated things.
There is lots about the point of sale product that seems half baked. They speak of a machine to process the tests but it does not exist. Who would make it and how much would it cost? Would point of care physicians invest in the machine and train people to operate it? Would they accept the liability for running an improper test? How could this test not impact the sales of the mass analyzer tests if it is any good at all? I just don't think any of this concept holds water.
